- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04150471
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
An Open Label, Observational Clinical Study to Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Have Any Grade of Adverse Events and Early Molecular Response Within 3 Months of Frontline Dasatinib Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will sign the consent forms for screening prior to frontline dasatinib therapy (1st) and the 3 month molecular test date (2nd). The molecular samples will be analyzed in the central lab as part of the screening procedure.
Subjects will be treated for a maximum of 60 months after allocation of the last subject on the assigned regimen (dasatinib 80mg QD), unless disease progression, treatment failure or unacceptable toxicity occurs, the subject withdraws consent, or the study is discontinued by the sponsor. Subjects who discontinue study therapy early due to disease progression or intolerance to study medication will continue to be followed yearly for survival for up to 5 years after allocation of the last subject. All subjects will be followed yearly for progression-free survival and overall survival.
For patients who continue their assigned treatment, safety assessments will be conducted every 6 months and cytogenetic assessment as investigator assessment.
Follow up visits after the last dose of study drug will be required at least every 4 weeks until all study related toxicities resolve to baseline (or CTC Grade ≤ 1), stabilize or are deemed irreversible.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Dong-Wook Kim
- Phone Number: +82-2-2258-7030
- Email: dwkim@catholic.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 137-701
- Recruiting
- Seoul St. Mary's Hospital
-
Contact:
- Sahee Park, MS
- Phone Number: +82-2-2258-7622
- Email: saheepark@catholic.ac.kr
-
Principal Investigator:
- Dong-Wook Kim, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult CML-CP Ph+ (Philadelpia) patients with BCR-ABL1 patients diagnosed within 3 months
- Adequate renal function defined as serum creatinine ≤ 3 times the institutional ULN(Upper limit of normal)
- Adequate hepatic function defined as: total bilirubin ≤ 2 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the institutional upper limit of normal (ULN).
- Adequate cardiac function (see exclusion criteria)
- Adequate pulmonary function (see exclusion criteria)
- Serum Na, K, Mg, and total serum Ca or ionized Ca levels must be greater than or equal to the institutional lower limit of normal. Subjects with low K, Mg levels, total serum Ca and/or ionized Ca must be replete to allow for protocol entry: Rescreening is permitted in the event of temporary biochemical abnormalities
- CML-CP Ph+ patients with CHR but with BCR-ABL level < 10% IS after 3 months of frontline dasatinib 100 mg treatment. And currently persisting any grade adverse events to dasatinib 100 mg QD
- ECOG(Eastern Cooperative Oncology Group) performance status 0-2
- Women must not be pregnant
Exclusion Criteria:
- Previous diagnosis of accelerated phase or blast crisis
- Documented any major ABL1 mutation
- A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive dasatinib
- Pulmonary arterial hypertension
- Congenital bleeding disorders
- Prior or concurrent malignancy, except for the following
- Subject with any anti-CML other than dasatinib
- Subjects with prior stem cell transplantation and/or high dose chemotherapy for CML
- Subjects currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes
- Subjects who were previously treated with over 100mg at second phase screening
- Subjects who are not tolerable to 80mg at second phase screening
- Patients who are pregnant or breast feeding or likely to become pregnant
- Prisoners or subjects who are involuntarily incarcerated
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of MMR
Time Frame: 12 month
|
Level of Bcr-Abl transcript (Conventional Q-RT-PCR)
|
12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess: Number and percentage of participants with treatment-related adverse events as assessed by CTCAE v4.0.
Time Frame: 12 months
|
Safety
|
12 months
|
MMR and MR4.5 rates by 5 years
Time Frame: 5 years
|
Level of Bcr-Abl transcript (Conventional Q-RT-PCR)
|
5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Sahee Park, Cancer Research Institute, The Catholic University of Korea
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAS-CHANGE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myelocytic Leukemia
-
Rambam Health Care CampusMiltenyi Biomedicine GmbHUnknownPhiladelphia Chromosome-positive Chronic Myelocytic LeukemiaIsrael
-
Seoul St. Mary's HospitalBristol-Myers SquibbUnknown
-
GlaxoSmithKlineCompletedLeukaemia, Myelocytic, AcuteUnited States
-
GlaxoSmithKlineTerminatedLeukaemia, Myelocytic, AcuteUnited States, Australia, Canada
-
Onconova Therapeutics, Inc.CompletedMyelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Chronic Myelocytic Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic LeukemiaUnited States
-
Anhui Provincial HospitalRecruitingAcute Myelocytic LeukemiaChina
-
The Affiliated Hospital of the Chinese Academy...Unknown
-
Grupo Cooperativo de Estudio y Tratamiento de las...Completed
-
Pierian BiosciencesDiaTech Oncology and Vanderbilt UniversityCompleted
-
Jewish General HospitalThe Leukemia and Lymphoma SocietyCompletedAcute Myelocytic LeukemiaCanada
Clinical Trials on RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)WithdrawnHead and Neck CancerUnited States
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
-
Assiut UniversityRecruitingInflammasome NLRP3 And IL-1B Gene Expression in COVID-19 PatientsEgypt
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Amina Fouad FaragCompletedCarcinoma Ex Pleomorphic Adenoma of Salivary Glands | Pleomorphic Adenoma of Salivary GlandsEgypt
-
Hunter College of City University of New YorkUniversidad Autonoma Juan Misael Saracho; Gobierno Autonomo Departamental De... and other collaboratorsCompleted
-
Nanjing First Hospital, Nanjing Medical UniversityZhongda HospitalRecruitingStroke, Ischemic | Stroke, Acute | Endovascular TreatmentChina
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingIschemic Stroke | Acute StrokeChina
-
Fayoum UniversityCompletedDiagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant LesionsLeukoplakia, Oral | Oral Lichen Planus | Potentially Malignant LesionsEgypt
-
Assiut UniversityCompletedDiarrhea, SecretoryEgypt